Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Geneart AG (OJ:G6A) - GENEART among the top 15 of the fastest growing technology companies in Germany - Among life science companies of this competition, GENEART ranks second - Cumulative corporate growth exceeds 800 percent over the past five years - Targeted investing in automation and process technologies allows further increase in capacities
Regensburg, October 23, 2008 - Above average growth in net sales earns GENEART No. 11 ranking in Deloitte's "Technology Fast 50" award of the fastest growing technology companies in Germany. The 50 winners of the growth prize awarded by audit and business consulting service provider Deloitte presented themselves in Dusseldorf last night. Rankings are based on cumulative net sales growth in percent over the past five years. GENEART, publicly traded global leader in gene synthesis and specialist in the field of Synthetic Biology, lifted net sales growth by more than 800 percent to €12.3 million over this period. Among life science companies GENEART ranked second in this competition.
"GENEART targeted investments in automation and process technologies over the past two years, which lifted production to a whole new level. Our capacities will increase fivefold by the end of 2010. These expanded capacities reflect the increased demand for synthetic genes, which emerged more and more from a niche to a mass product", stated Christian Ehl, CEO of GENEART AG.
Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241 Munich Germany Phone: +49-(0)89-8896906-10 Fax: +49-(0)89-8896906-66 info@better-orange.de www.better-orange.de
Legal Information This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.
About GENEART AG: In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ more than 190 people. Since May 2006, GENEART is listed on the German Stock Exchange.
